Preventing Transfusion Related Complications in a Recipient of a Blood Transfusion

• US 20100080781A1
• Filed: 12/03/2009
• Published: 04/01/2010
• Est. Priority Date: 06/02/2000
• Status: Active Grant

• Current Assignee: Terumo BCT Biotechnologies, LLC (Terumo Corporation)
• Original Assignee: Caridianbct Biotechnologies LLC (Baxter International Inc.)
• Inventors: LI, Junzhi, GOODRICH, Raymond P.
• Granted Patent: US 7,892,535 B2
• Time in Patent Office: Days
• US Class Current: 424/93.700
• CPC Class Codes: A01N 1/0215 Disinfecting agents, e.g. antimicrobials for preserving living parts
• CPC Class Codes: A01N 1/0226 Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/525 Isoalloxazines, e.g. riboflavins, vitamin B2
• CPC Class Codes: A61K 35/14 Blood; Artificial blood perfluorocarbons A61K31/02; umbilical cord blood A61K35/51; haemoglobin A61K38/42
• CPC Class Codes: A61K 35/19 Platelets; Megacaryocytes
• CPC Class Codes: A61K 41/0023 Agression treatment or altering

Abstract

This invention is directed toward a process for reducing transfusion related complications in a recipient of an allogeneic blood transfusion by adding to the blood to be transfused a photosensitizer comprising riboflavin, irradiating the blood and riboflavin with light, transfusing the irradiated blood into a recipient, and reducing a transfusion related complication by the recipient to cells in the donor blood.

The invention is also directed towards a process for preventing rejection of a donor organ by a recipient comprising the steps of transfusing the recipient of the donor organ with treated platelets; and transplanting the donor organ into the recipient.

Claims

1. A process for preventing rejection of a donor organ by a recipient comprising the steps of:

transfusing the recipient of the donor organ with treated platelets; and

transplanting the donor organ into the recipient.

2. The process of claim 1 wherein the treated platelets further comprise platelets treated with riboflavin and light.

3. The process of claim 1 wherein the step of transfusing the recipient further comprises transfusing the recipient with treated platelets for a period of time before the organ transplant.

4. The process of claim 1 wherein the step of transfusing the recipient further comprises transfusing the recipient with treated platelets multiple times before the organ transplant.

5. The process of claim 1 wherein the donor organ to be transplanted into the recipient is allogeneic.

6. The process of claim 1 wherein the donor organ to be transplanted into the recipient is xenogeneic.

7. The process of claim 1 wherein the treated platelets are from an allogeneic donor.

8. The process of claim 1 wherein the treated platelets prevent the development of antibodies to the transplanted organ in the transplant recipient.

9. The process of claim 1 wherein the donor organ is a solid organ.

10. The process of claim 9 wherein the donor organ is a heart.